Jan 6, 2026 03:20PM Jefferies on Aclaris Therapeutis (ACRS): 'We see this data building the foundation to support upward momentum'

Dec 19, 2025 04:01PM Aclaris Therapeutics added to NASDAQ Biotechnology Index

Nov 6, 2025 08:14AM Aclaris Therapeutics (ACRS) Tops Q3 EPS by 1c

Oct 15, 2025 07:13AM Cantor Fitzgerald Reiterates Overweight Rating on Aclaris Therapeutis (ACRS): 2026 Rich in Catalysts

Aug 7, 2025 08:35AM Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c

Jul 29, 2025 04:02PM Aclaris reports positive Phase 2a results for atopic dermatitis drug

Jul 28, 2025 08:45AM Aclaris Therapeutics names Roland Kolbeck as chief scientific officer

Jul 9, 2025 04:36PM Piper Sandler Assumes Aclaris Therapeutis (ACRS) at Overweight, PT $6

Jun 30, 2025 09:32AM Aclaris Therapeutics (ACRS) Added to the Russell 2000 and Russell 3000 Indexes

Jun 25, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Aclaris Therapeutis (ACRS)

Jun 9, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Aclaris Therapeutis (ACRS)

Jun 2, 2025 07:02AM Aclaris Therapeutics (ACRS) Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

May 28, 2025 07:06AM Aclaris Therapeutics (ACRS) Gains ~20% Following Wedbush Coverage Launch

May 28, 2025 07:05AM Wedbush Starts Aclaris Therapeutis (ACRS) at Outperform

May 14, 2025 07:52AM Aclaris Therapeutis (ACRS) PT Lowered to $16 at H.C. Wainwright

May 8, 2025 04:31PM Aclaris Therapeutics (ACRS) Tops Q1 EPS by 2c

Apr 29, 2025 07:02AM Aclaris Therapeutics (ACRS) Appoints Jesse Hall as Chief Medical Officer

Apr 22, 2025 06:59AM Aclaris Therapeutics (ACRS) Secures U.S. Food and Drug Administration IND Clearance for ATI-052

Mar 7, 2025 07:06AM Scotiabank Starts Aclaris Therapeutis (ACRS) at Sector Outperform

Feb 27, 2025 07:02AM Aclaris Therapeutics (ACRS) reported Q4 Revenue

Feb 12, 2025 06:51AM Aclaris Therapeutics (ACRS) Highlights Unique Properties of ATI-2138

Jan 30, 2025 04:04PM Aclaris Therapeutics (ACRS) Forms New Scientific Advisory Board

Dec 23, 2024 06:46AM H.C. Wainwright Upgrades Aclaris Therapeutis (ACRS) to Buy

Dec 19, 2024 04:34PM Aclaris Therapeutics (ACRS) Files for 35.56M Share Offering by Selling Stockholders

Nov 20, 2024 03:46PM Cantor Fitzgerald Upgrades Aclaris Therapeutis (ACRS) to Overweight

Nov 19, 2024 11:07AM Goldman Comments on Aclaris Therapeutics (ACRS), Shares up 33% Today, Up 245% Over Past 30 Days

Nov 19, 2024 07:19AM Leerink Partners Upgrades Aclaris Therapeutis (ACRS) to Outperform, Shares +20% in Premarket Session

Nov 19, 2024 02:35AM BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy

Nov 19, 2024 02:34AM Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy

Nov 18, 2024 02:54PM Piper Sandler Upgrades Aclaris Therapeutis (ACRS) to Overweight, PT $13

Nov 18, 2024 12:34PM Stifel Reiterates Hold Rating on Aclaris Therapeutis (ACRS)

Nov 18, 2024 08:11AM Aclaris Therapeutics (ACRS) Announces 35.56M Share Offering at $2.25/sh

Nov 18, 2024 08:10AM Aclaris Therapeutics (ACRS) Announces Exclusive, Global License Agreement with Biosion

Nov 6, 2024 12:46PM Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel

Sep 18, 2024 06:44AM H.C. Wainwright Reiterates Neutral Rating on Aclaris Therapeutis (ACRS)

Sep 18, 2024 06:21AM BTIG Reiterates Neutral Rating on Aclaris Therapeutis (ACRS)

Jul 16, 2024 04:03PM Aclaris Therapeutics (ACRS) Sells OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5M